Table 2. Initial patient characteristics anti-AQP4 cohort.

Patient	Onset (gender)	Symptoms duration (d)	Clinical findings	VA (RE, LE; (logMAR)	RAPD (RE, LE)	Colour VA (Ishihara plates, RE, LE)	Red desaturation (present, absent)	Average GCL; RE, LE (µm)	Average RNFL; RE, LE (µm)	Pain (retrobulbar or on movement)	MRI brain and orbits demyelination protocol	Initial treatment
1	18 (M)	Decrease in left VA (3)	Pale left ONH	0, 3	0, +3	14/14, 0/14	NA	54, 55	51, 50	Absent	Marked high signal in the left retrobulbar optic nerve	Admitted for 3/7 IVMP with oral taper
2	55 (F)	Decrease in left VA (4)	Normal ONH bilaterally	0, 2.7	0, +2	14/14, 0/14	Present	68, 68	81, 87	Absent	No evidence of optic neuritis	Admitted for 3/7 IVMP with oral taper
3	33 (F)	Diplopia worse when looking to right (6)	Normal ONH, right INO	0, 0	0, 0	14/14, 14/14	Absent	75, 74	99, 94	Absent	High signal in the canalicular components of both optic nerves extending back to chiasm with expansion of the chiasm	Admitted for 3/7 IVMP with oral taper
4	51 (M)	Decrease in vision in BE, particular night vision (63)	Pale ONH bilaterally	0.2, 0.2	0, 0	3/14, 3/14	Present BE	60, 61	67, 63	Absent	Evidence of chiasmitis with T2 weighted chiasmal abnormalities	Admitted for 5/7 IVMP with oral taper

F: Female; M: Male; VA: Visual acuity; ONH: Optic nerve heads; RAPD: Relative afferent pupillary defect; RE: Right eye; LE: Left eye; BE: Both eyes; GCL: Ganglion cell layer; RNFL: Retinal nerve fibre layer; MRI: Magnetic resonance imaging; NA: Not applicable; IVMP: Intravenous methylprednisolone; INO: Intranuclear ophthalmoplegia.